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A B S T R A C T   
Introduction: Alarmins ((IL-25, IL-33 and thymic stromal lymphopoietin (TSLP)) are known to promote Th2 
inflammation and could be associated with eosinophilic airway infiltration. They may also play a role in airway 
remodeling in chronic airway obstructive diseases such as asthma and chronic obstructive pulmonary disease 
(COPD). IL-23 and IL-36 were shown to mediate the neutrophilic airway inflammation as seen in chronic airway 
obstructive diseases. Objectives: The purpose of this project was to determine the expression and the production 
of these cytokines from induced sputum (IS) in patients with chronic airway obstructive diseases including 
asthmatics and COPD. The relationship of the mediators with sputum inflammatory cellular profile and the 
severity of airway obstruction was assessed. 
Methods: The alarmins (IL-25, IL-33 and TSLP) as well as IL-23 and IL-36 concentrations were measured in IS 
from 24 asthmatics and 20 COPD patients compared to 25 healthy volunteers. The cytokines were assessed by 
ELISA in the IS supernatant and by RT-qPCR in the IS cells. 
Results: At protein level, no difference was observed between controls and patients suffering from airway 
obstructive diseases regarding the different mediators. IL-36 protein level was negatively correlated with sputum 
eosinophil and appeared significantly decreased in patients with an eosinophilic airway inflammation compared 
to those with a neutrophilic profile and controls. At gene level, only IL-36, IL-23 and TSLP were measurable but 
none differed between controls and patients with airway obstructive diseases. IL-36 and IL-23 were significantly 
increased in patients with an neutrophilic inflammatory profile compared to those with an eosinophilic 
inflammation and were correlated with sputum neutrophil proportions. None of the mediators were linked to 
airway obstruction. 
Conclusions: The main finding of our study is that patients with eosinophilic airway inflammation exhibited a 
reduced IL-36 level which could make them more susceptible to airway infections as IL-36 is implicated in 
antimicrobial defense. This study showed also an implication of IL-36 and IL-23 in airway neutrophilic 
inflammation in chronic airway obstructive diseases.   
1. Introduction 
As asthma and COPD combine multiple phenotypes and overlap 
between them, it has been recently suggested to consider these pathol-
ogies together as “chronic airway obstructive diseases” to select 
appropriate therapies. Moreover, it was proposed to consider patients 
suffering from airway diseases according to “treatable traits” such as 
eosinophilic airway inflammation rather than using the conventional 
diagnostic labels [1–3]. 
Alarmins ((namely thymic stromal lymphopoietin (TSLP), Inter-
leukin (IL)-33 and IL-25)) are cytokines released by the bronchial 
epithelial cells, among others, in case of danger signal that can be 
endogenous or exogenous. Indeed, damage-associated molecular pat-
terns (DAMPs) which include IL-33 itself [4], induce a pro-inflammatory 
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and immune response in the same way than exogeneous pathogen- 
associated molecular patterns (PAMPs) [5]. The released alarmins can 
in turn initiate a Th2 response and local eosinophil recruitment in 
asthma context [6]. Targeting those mediators was recently thought to 
be of interest as they are up-stream of the Th2 cascade [7,8] and 
promising clinical studies are ongoing [9]. Inhibition of the cytokine 
triad could also represent a treatment opportunity in the future [10]. 
TSLP is an IL-2 family member shown to be linked to atopic diseases 
[11] but also to non-atopic pathologies such as chronic obstructive 
pulmonary disease (COPD) [12]. Tezepelumab, an anti-TSLP antibody, 
has recently shown beneficial effects in a clinical trial targeting severe 
asthma [13]. IL-33 is an IL-1 family cytokine, and once secreted and 
fixed to its ST2 receptor (an IL-1 receptor like-1 also known as IL1RL1 
and which possesses transmembrane and soluble isoforms), mediates the 
group 2 innate lymphoid cells (ILC2) activation and inflammatory cy-
tokines production. Increase in lung IL-33 and ST2 expressions have 
been observed both in asthma and COPD [14]. Moreover, single nucle-
otide polymorphism (SNPs) in TSLP and IL-33 genes were identified to 
be linked to asthma susceptibility [15]. IL-25, also known as IL-17E, 
although being part of IL-17 cytokine family, has a pleiotropic nature 
and possess distinct functions [16]. It is implicated in Th2-dependent 
immunity and is involved in the development of “Th2-high allergic 
asthma”, a subtype of asthma showing good inhaled corticosteroids 
(ICS) response [17]. In the same manner, sputum high IL-25 gene 
expression level appeared closely related to high IL-5 expression pattern 
[18]. IL-25 was observed to be increased in the blood of COPD patients 
and its production was promoted by TSLP [19]. Finally, the triad TSLP, 
IL-33 and IL-25 were also reported to be involved in the airway 
remodeling, a classical asthma feature [20]. 
IL-36, an IL-1 superfamily member, is also produced by the lung 
epithelium in response to stress such as viral or bacterial infections or 
house dust mite stimulation [21]. It is known to be linked to a Th-1 and 
Th-17 response and may contribute to the neutrophilic infiltration seen 
in asthma and COPD [22]. 
Finally, IL-23, an IL-12 family member, regulates chronic inflam-
matory processes. Anti-IL-23 (Risankizumab) are used for chronic skin 
diseases such as psoriasis [23]. IL-23 drives the Th-17 inflammation and 
a mouse asthma model revealed that an increased airway IL-23 
expression induced a local eosinophil and neutrophil recruitment and 
Th2 cytokines production [24]. It could then be considered as an 
interesting potential target for therapies in severe asthma [25] as it has 
been related to the severity of airway obstruction [26]. IL-23 appeared 
also increased in bronchial biopsies of COPD patients compared to 
healthy controls [27]. 
Induced sputum (IS) is a non-invasive method to collect cells from 
airways that is useful both as a research tool and in the management of 
asthmatic patients in clinical practice [28]. In addition, induced sputum 
has been pivotal developing the concept of airway inflammatory 
phenotype [29]. 
As the literature regarding the sputum levels of these mediators is 
limited in chronic airway diseases, this study aimed to measure the 
alarmins (TSLP, IL-33 and IL-25) as well as IL-23 and IL-36 protein and 
gene expression levels in sputum of patients suffering from chronic 
airway obstructive diseases and in a group of healthy controls. In 
addition, the relationship between these proteins production and spe-
cific traits such as sputum inflammatory cellular profile and the severity 
of airway obstruction was assessed in order to detect particular pheno-
types/endotypes. 
2. Material and methods 
2.1. Subjects 
Patient characteristics are given in Table 1. Twenty-four asthmatic 
Table 1 
Demographic and functional characteristics.   
Controls (n = 25) Airway obstructive diseases 
(n = 44) 
P value COPD 
(n = 20) 
Asthmatic 
(n = 24) 
P value 
Sex (M/F) 11/14 17/27 0.80 9/11 8/16 0.67 
Age (years) 55 ± 14 54 ± 16 0.81 64 ± 8$$$ 46 ± 17 0.0002 
Smoking status(NS/ExS/S) 19/4/2 17/15/12 0.02 0/12/8 17/3/4 <0.0001 
Pack-years 5 ± 9 20 ± 20 <0.001 35 ± 17 ***$$$ 9 ± 14 0.0024 
BMI (kg/m2) 25 ± 3 25 ± 4 0.68 24 ± 3 26 ± 4 0.28 
Atopy (yes/no) 5/20 22/22 0.02 6/14 16/8 0.0023 
FeNO (ppb) 20 (16–29) 27 (10–46) 0.30 29 (10–56) 26 (10–44) 0.55 
FEV1 (% predicted) 111 ± 15 64 ± 26 <0.0001 48 ± 18***$$$ 77 ± 25*** <0.0001 
FEV1 post BD (% predicted) 117 ± 16 69 ± 27 <0.0001 52 ± 20***$$$ 88 ± 23*** <0.0001 
FVC (% predicted) 116 ± 19 82 ± 22 <0.0001 72 ± 20***$ 90 ± 21*** <0.0001 
FVC post BD (% predicted) 116 ± 19 86 ± 20 <0.0001 77 ± 20***$$$ 102 ± 14 <0.0001 
FEV1/FVC (%) 79 ± 5 64 ± 14 <0.0001 55 ± 10***$$$ 71 ± 12** <0.0001 
FEV1/FVC post BD (%) 84 ± 5 65 ± 17 <0.0001 54 ± 10***$$$ 80 ± 11 <0.0001 
RV (%predicted)  147 ± 52  187 ± 37 125 ± 38 0.0038 
TLC (% predicted)  101 ± 23  115 ± 16 105 ± 13 0.17 
DLCO (% predicted)  57 ± 21  44 ± 13 74 ± 14 0.0004 
KCO (% predicted)  76 ± 28  55 ± 15 84 ± 11 0.0007 
ICS (yes/no) 0/25 29/15  11/9 18/6 <0.0001 
OCS (yes/no) 0/25 5/39  3/17 2/22 0.15 
LABA (yes/no) 0/25 35/9  14/6 21/3 <0.0001 
LAMA (yes/no) 0/25 12/32  11/9$$$ 1/23 <0.0001 
SABA (yes/no) 0/25 12/32  2/18$ 10/14 0.0004 
SAMA (yes/no) 0/25 20/24  11/9 9/15 0.0001 
LTRA (yes/no) 0/25 7/37  1/19 6/18 0.01 
Severity status    GOLD 1: 1 6 mild      
GOLD 2: 10 7 moderate      
GOLD 3: 7 11 severe- refractory      
GOLD 4: 2   
Results are expressed as mean ± SD or median (25–75%). NS: non-smoker; ExS: ex-smoker; S: smoker; BMI: body mass index; FeNO: exhaled nitric oxide. FEV1: forced 
expiratory volume in 1 s; FVC: forced vital capacity; RV: residual volume; TLC: total lung capacity; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: gas 
transfer coefficient; ICS: inhaled corticosteroids; OCS: oral corticosteroids; LABA: long acting beta 2 agonist, LAMA: long acting muscarinic antagonist. SABA: short 
acting beta agonist; SAMA: short acting muscarinic antagonist; LTRA: leukotriene receptor antagonist. *P < 0.05, **P < 0.01, ***P < 0.001 vs healthy subjects. $P <
0.05, $$P < 0.01, $$$P < 0.001 vs asthmatic subjects. 
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and 20 COPD patients were recruited through the outpatient clinic and 
pulmonary rehabilitation centre (CHU, Sart-Tilman, Liege). Character-
istics of patients classified using classical diagnosis can be found in 
Table 1. Asthma was diagnosed following the GINA guidelines (htt 
p://ginasthma.org/). Mild and moderate asthma were defined as pa-
tients without maintenance treatment or with a dose of ICS lower than 
1000 μg beclomethasone per day, associated with a FEV1 ≥ 80% pre-
dicted. Severe and refractory asthma were defined according to ATS 
criteria [30]. Diagnosis of COPD was made according to GOLD criteria 
(http://goldcopd.org/). 
Twenty-five healthy volunteers were enrolled by advertisement 
among the hospital and staff. This study was approved by the ethics 
Committee of CHU Liège and all subjects gave written informed consent 
for participation. 
2.2. Lung function tests 
Lung function assessment was performed for all patients as previ-
ously described and according to ATS/ERS standard criteria [31–33]. 
2.3. Sputum induction and processing 
The sputum was induced and processed as previously described 
[34,35]. Cell viability was determined by trypan blue exclusion and the 
differential cell count was performed by counting 500 non-squamous 
cells on cytospins stained with May-Grünwald-Giemsa (Table 2). 
2.4. Immunoassays 
The concentrations of alarmins (IL-25, IL-33 and TSLP) and IL-23 
contained in the sputum supernatant were assessed by ELISA multi-
plex using Fluorokine® Multianalyte Profiling (MAP) Kits and a Duoset 
kit was used for IL-36 (R and D systems, Minneapolis, USA) according to 
the manufacturer’s instructions. Detection limits were 50, 0.2, 0.55, 75 
and 33 pg/ml for IL-25, IL-33, TSLP, IL-23 and IL-36 respectively. 
Spiking experiments of cytokines in sputum supernatants showed that 
recovery was between 80% and 120% for all the analytes. Results are 
displayed in Table 3. 
2.5. RNA extraction and RT-qPCR methods 
Mediator gene expression levels were assessed in a subgroup of pa-
tients composed of 14 asthmatics, 15 COPD patients and 8 healthy 
controls. 
These steps were performed exactly as recently described [36]. Se-
quences of primers and probes are listed in the online supplementary 
material. They were all obtained from IDT (Integrated DNA Technolo-
gies, Skokie, IL, USA). PCR efficiencies were calculated using qbase +
qPCR analysis software (Biogazelle, Zwijnaarde, Belgium) and were all 
between 1.9 and 2.1 except for IL-25 which was impossible to obtain. 
The same program was used to obtain relative quantitation in gene 
expression using the 2− ΔΔCt method. HPRT1 and GNB2L1 were used as 
reference genes as also previously reported [36]. Finally, the expression 
of IL-5 was used as control as this gene was known to be linked with 
eosinophilic airway inflammation in asthma [37,38]. IL-8 was assessed 
as marker of neutrophilic inflammation as its expression was correlated 
with neutrophilic phenotype [39]. Results can be found in Table 3. 
2.6. Statistical analysis 
Patient demographic and functional characteristics were expressed 
as mean ± SD. Comparisons between patient groups were performed 
using unpaired t tests. Chi-square test was applied for categorical vari-
ables. Sputum cell counts and cytokines levels were expressed as median 
(25–75%). Mann-Whitney tests were used to compare 2 groups and 
Kruskal Wallis tests were applied when more than 2 groups were 
compared. Correlations were calculated with Spearman’s rank correla-
tion analysis. All statistical analyses were performed with Graphpad 
Prism 7.0 (Graphpad Software San Diego, CA, USA). Differences were 
considered statistically significant when a two-sided p-value was < 0.05. 
3. Theory 
Little is known about sputum alarmins (IL-25, IL-33 and TSLP) as 
well as IL-23 and IL-36 in the context of chronic obstructive diseases 
such as asthma and COPD. The objective of this study was to determine 
Table 2 
Sputum cell counts.   
Controls 
(n = 25) 
Airway obstructive 
diseases 
(n = 44) 
P value 
Sputum weight (g) 3.7 (2.9–5.2) 2.6 (1.5–5.1) 0.08 
Squamous cells (%) 16 (8–26) 3 (1–11) <0.0001 
Viability (%) 80 (75–89) 76 (64–85) 0.20 
106cells/g 0.9 (0.5–1.9) 3.3 (1.6–7.0) <0.0001 
Macrophages % 17 (13–44) 10 (4–26) <0.05 
Macrophages 103/g 188 (124–713) 395 (173–2711) 0.25 
Neutrophils % 76 (46–82) 67 (40–92) 0.80 
Neutrophils 103/g 682 
(281–1236) 
1781 (865–5781) <0.01 
Eosinophils % 0.0 (0.0–1.0) 3.4 (0.0–13.6) <0.05 
Eosinophils 103/g 0.0 (0.0–16.9) 64.5 (0.0–516.0) <0.01 
Epithelial cells % 2.2 (0.9–4.4) 1.2 (0.0–5.5) 0.28 
Epithelial cells 103/g 25.0 
(6.7–82.5) 
69.5 (0.5–120.3) 0.71 
Lymphocytes % 1.8 (0.6–2.9) 1.4 (0.2–2.0) 0.19 
Lymphocytes 103/g 18.0 
(7.0–32.2) 
36.0 (6.7–122.5) 0.16 
Inflammatory 
phenotypes    
Eosinophilic (≥3%)  17  
Neutrophilic (≥76%)  13  
Mixed granulocytic  5  
Paucigranulocytic  9  
Results are expressed as median (25–75%). 
Table 3 
Alarmins (IL-25, IL-33, TSLP), IL-23 and IL-36 protein and gene expression 
levels.   




Detectable IL-33 (%) 6/20 (30) 15/44 (34) >0.99 
IL-33 (pg/ml) 0.0 (0.0–0.2) 0.0 (0.0–0.2) 0.98 
Detectable IL-25 (%) 6/20 (30) 9/44 (20) 0.53 
IL-25 (pg/ml) 0.0 (0.0–163.2) 0.0 (0.0–0.0) 0.58 
Detectable TSLP (%) 10/20 (50) 18/44 (41) 0.59 
TSLP (pg/ml) 0.3 (0.0–0.5) 0.0 (0.0–0.5) 0.48 
Detectable IL-23 (%) 9/20 (45) 18/44 (41) 0.79 
IL-23 (pg/ml) 0.0 (0.0–88.7) 0.0 (0.0–116) 0.34 
Detectable IL-36 (%) 12/13 (92) 26/32 (81) 0.65 
IL-36 (pg/ml) 172.4 
(74.5–424.7) 
310.6 (160.8–468.3) 0.34 
Detectable IL-33 gene 
(%) 
0/8 (0) 0/29 (0) >0.99 
Detectable TSLP gene 
(%) 
5/8 (62) 23/29 (79) 0.37 
TSLP (Fold change) 1.0 ± 2.6 1.5 ± 2.6 0.38 
Detectable IL-23 gene 
(%) 
8/8 (100) 27/29 (93) >0.99 
IL-23 (Fold change) 1.1 ± 4.0 1.2 ± 3.3 0.89 
Detectable IL-36 gene 
(%) 
7/7 (100) 26/29 (90) >0.99 
IL-36 (Fold change) 1.0 ± 4.9 1.4 ± 3.8 0.92 
Detectable proportions were compared using Fisher tests. Mediators levels are 
expressed as median (25–75%) and were compared with Mann-Whitney tests. 
Data for gene expression are expressed as geometric mean ± SD and were 
compared with Mann-Whitney tests. 
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the expression and the production of the alarmins (IL-25, IL-33 and 
TSLP), and IL-23 and IL-36 in induced sputum of patients with chronic 
airway obstructive diseases including asthmatics and COPD and to 
compare them to healthy subjects. The relationship of the mediators 
with sputum inflammatory cellular profile and the severity of airway 
obstruction was also assessed. 
4. Results 
4.1. Demographic and functional patient characteristics 
Patients were well matched according to sex, age and BMI but not for 
tobacco habits. Patients suffering from asthma and COPD exhibited 
pulmonary function parameters significantly impaired compared to 
healthy controls (Table 1). 
4.2. Sputum cell counts 
Patients had significantly a higher sputum total cell number and a 
higher number of neutrophils compared to healthy subjects. Moreover, 
the percentage and number of eosinophils were significantly higher. In 
counterpart, the proportion of squamous cells and macrophages 
appeared significantly lower (Table 2). 
4.3. Mediators 
At protein level, among all the analyzed mediators, the levels of IL-25 
were poorly detectable in the majority of the samples. Between a third 
and a half of patients gave measurable results for TSLP, IL-23 and IL-33 
but the levels of these mediators did not appear different between 
groups. IL-36 was detectable in the majority of the samples but did not 
differ between groups neither (Table 3). 
At gene level, only IL-36, IL-23 and TSLP gave measurable expres-
sions and none of them were different between groups (Table 3). 
4.4. Relationship with demographic characteristics 
None of the mediators differed between men and women at protein 
or gene level. None correlated with age, BMI or pack-year values. No 
differences was noted between the different tobacco status groups or the 
atopic status. 
4.5. Relationship with airway obstruction 
There was no relationship between any of the mediator at the protein 
or gene expression levels and the lung function parameters including pre 
and post bronchodilation FEV1 and FVC but also TLC, RV, DLCO and 
KCO values. 
In addition, patients presenting fixed airway obstruction (defined as 
post bronchodilation FEV1 % predicted < 80% and FEV1/FVC < 70%, n 
= 19/34 subjects with available post bronchodilation values) did not 
differ from those patients without (n = 15/34) for alarmins and cyto-
kines at protein and gene level (data not shown). 
4.6. Relationship with airway inflammation 
In all subjects combined (n = 69), IL-36 protein level was negatively 
correlated with sputum eosinophil percentage and number (r = − 0.44 
and r = − 0.43, p < 0.01 respectively, Fig. 1A). The correlation obtained 
between IL-36 level and sputum neutrophil count was not significant (r 
= 0.25, p = 0.11). 
When the patients were classified according to inflammatory phe-
notypes, IL-36 appeared significantly decreased in patients with a 
eosinophilic inflammation compared to those with a neutrophilic airway 
inflammation and controls (Fig. 1B). 
There was no correlation between alarmins or IL-23 protein levels 
and sputum cellular inflammatory profile. 
Regarding the genes, the IL-5 sputum expression used as control gene 
of airway eosinophilia was notably increased in patients presenting an 
eosinophilic inflammation compared to other phenotypes (Fig. 2A). 
Similarly, IL-8 expression, a control gene for airway neutrophilia, was 
significantly increased in patients with neutrophilic inflammation 
compared to others (Fig. 2B). 
In all subjects combined IL-36 gene expression was correlated with 
the sputum neutrophil percentage (r = 0.58p < 0.001, Fig. 3A) but not 
with eosinophil percentage (r = − 0.21 and p = 0.24). Similarly to what 
is seen at protein level, IL-36 gene expression was significantly increased 
in patients with a neutrophilic airway inflammation compared to those 
with an eosinophilic inflammation (Fig. 3B). In the same manner, IL-23 
expression exhibited a significant correlation with the sputum neutro-
phil percentage in all subjects (r = 0.57, p < 0.001, Fig. 4A) and patients 
with a neutrophilic inflammation had higher expression level compared 
to those with eosinophilic airway inflammation (Fig. 4B). There was no 
correlation between any sputum cell type and TSLP gene expression in 
the whole cohort. However, in obstructive airway diseases, TSLP 
expression appeared negatively correlated with sputum eosinophil ab-
solute value (r = − 0.51, p < 0.05, Fig. 5A) and a trend was observed for 
a correlation with eosinophil percentage (r = − 0.39, p = 0.07, Fig. 5B). 
None of the mediators appeared correlated with the exhaled nitric 
oxide (FeNO) values. 

















































Fig. 1. (A) Correlation between IL-36 protein level and sputum eosinophil 
percentage. (B) Sputum IL-36 concentrations according to airway inflammatory 
phenotype. Data were displayed as Box and Whiskers (Min-Max) and were 
compared with Kruskal Wallis (p < 0.05) then Dunn’s multiple comparisons 
tests gave a p value < 0.05 as indicated. Eosinophilic phenotype: sputum 
eosinophil count ≥ 3%, neutrophilic: sputum neutrophil count ≥ 76%. Those 
who combined both were not considered in this analysis. 
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4.7. Relationship with treatments 
Among patients, no differences were observed between those treated 
with beta-2 agonists and those without. IL-36 gene expression in patients 
treated with ICS showed a reduced expression compared to those not 
receiving ICS (0.7 ± 3.3 vs 2.1 ± 3.6, p = 0.05). Likewise, IL-23 gene 
expression in patients with ICS showed a lower expression than steroid 
naïve patients (0.8 ± 2.8 vs 2.0 ± 3.4, p < 0.05). 
5. Discussion 
Overall our study showed that the sputum protein and gene levels of 
alarmins (IL-25, IL-33 and TSLP), IL-23 and IL-36 did not differ between 
patients suffering from chronic airway obstructive diseases and healthy 
controls. The main finding from our study is that there is an inverse 
relationship between the level of IL-36 and the magnitude of the airway 
eosinophilic inflammation while it positively correlated with airway 
neutrophilic inflammation. To the best of our knowledge, our study is 
the first to report on the levels of sputum IL-36 in patients suffering from 
chronic airway obstructive diseases. 
IL-36 is well known to be activated in psoriasis where it induces 
neutrophil and Th17 cells recruitment and activation [40]. In asthma 
and COPD, literature appeared limited. Murine asthma models showed 
airway neutrophil but not eosinophil recruitment induced by IL-36 as 
well as an increase of chemokines linked to neutrophil chemotaxis [22]. 
In vitro studies highlighted the IL-36 production by human airway 
epithelial cells [41] and only one study described an elevated IL-36 gene 
expression in rhinovirus infected human bronchial epithelial cells in a 
context of asthma [42]. Interestingly, in our study, patients displaying 
an eosinophilic airway inflammation have lower IL-36 protein levels 
that healthy subjects which could make them more prone to bacterial 
and viral infections as IL-36 is crucial for lung innate immunity [43]. 
Supporting this hypothesis, the eosinophilic phenotype in airway 
obstructive diseases were shown to be more susceptible to exacerbations 
[44–46]. Our current finding is in the same line as what has been re-
ported by Da Silva et al. who showed that gene of antiviral defense were 
decreased in eosinophilic asthmatics [47]. Finally, ICS treatment is 
known to reduce IL-1-like cytokines [48] and this may explain the 
decrease of IL-36 level in our patients treated with ICS compared to 
those without. 
IL-23, for its part, induces IL-17 release which in turn stimulates 
neutrophil chemoattractant agents [49]. As expected we found a sig-
nificant correlation between IL-23 gene levels and sputum neutrophil 
proportions. As for IL-36, we found a significant decrease of IL-23 
























































Fig. 2. (A) Sputum IL-5 gene expression according to airway inflammatory 
phenotype (B) Sputum IL-8 gene expression according to airway inflammatory 
phenotype. Data were displayed as Box and Whiskers (Min-Max) and were 
compared with Mann-Whitney tests. Eosinophilic phenotype: sputum eosino-
phil count ≥ 3%, neutrophilic: sputum neutrophil count ≥ 76%. 

















































Fig. 3. (A) Correlation between IL-36 gene expression level and sputum 
neutrophil percentage. (B) Sputum IL-36 gene expression according to airway 
inflammatory phenotype. (A) • represent subjects with chronic airway diseases, 
Δ represent healthy controls. (B) Data were displayed as Box and Whiskers 
(Min-Max) and were compared with Kruskal Wallis (p < 0.05) then Dunn’s 
multiple comparisons tests gave a p value < 0.05 as indicated. Eosinophilic 
phenotype: sputum eosinophil count ≥ 3%, neutrophilic: sputum neutrophil 
count ≥ 76%. Those who combined both were not considered in this analysis. 
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decreased IL-23 expression in human blood macrophages induced by 
glucocorticoids, which was mediated by p38 MAPK inhibition [50]. 
However, the underlying mechanisms that repress airway IL-23 in our 
study needs more investigation. 
Another original aspect of our work is the search for the presence of 
alarmins in the airways of patients suffering from chronic airway 
obstructive diseases as these mediators have been recently put forward 
as key epithelial derived mediators in regulating eosinophilic airway 
inflammation [51]. Unfortunately, TSLP, IL-33 and IL-25 were poorly 
detectable not only at protein level but also at gene level and did not 
show difference between groups. 
Surprisingly, a negative correlation was noted between TSLP 
expression and sputum eosinophils in our study. However, it has been 
recently observed that high sputum TSLP mRNA level in viral induced 
asthma exacerbation was not associated with sputum eosinophils [52]. 
Moreover, bronchoalveolar lavage TSLP expression in asthmatics has 
been also recently shown to be rather linked to lung neutrophil infil-
tration [53]. In addition TSLP was shown to be involved in neutrophilic, 
Th2 low airway inflammation and link to IL-17 release [54]. 
IL-33, although not detectable in the complete set of patients, was 
not different from healthy controls. IL-33 has been reported to be 
quickly oxidized after its secretion which could have alter the detection 
[55]. Finally IL-25 was also hard to detect in sputum in our study. 
The explanations for the low detection levels of alarmins in our study 
are multiple. Firstly, as alarmins are epithelial-derived cytokines, and 
the proportion of epithelial cells is rather low in sputum, it could be that 
the amount produced is insufficient for detection. Secondly, the time 
window of investigation may not be optimal for detection as alarmins 
were shown to be essentially released by the epithelium during an 
exacerbation period [55] whereas our patients were stable at the time of 
sputum sampling. Thirdly, the treatment effect may have play a role as a 
large proportion of the patients are treated with ICS and long acting beta 
2 agonist (LABA). However, although glucocorticoids have been shown 
to decrease IL-25 expression [56,57], alarmins are mainly considered as 
poorly sensitive to corticosteroids and linked to cortico-resistance 
[9,56,58,59]. Beta 2 receptor agonists for their parts, were observed 
to increase the release of alarmins [60,61] but no effect was noticed in 
our study maybe due to the low patient number in the no LABA group. 
Indeed, the last limitation of this study was the limited sample size 
which may have reduced the power of the sub-analyses to detect sig-
nificant differences between controls and patients. These findings are 
then needed to be confirmed in larger cohorts. 
In conclusion, the main finding of our study is the demonstration of 
reduced IL-36 level in the patients with eosinophilic airway inflamma-
tion. We believe that it could make the patients more susceptible to 
airway infections as IL-36 has a role in antimicrobial defense and partly 
explain why eosinophilic airway inflammation may make patients with 
obstructive airway disease prone to exacerbate. 
















































Fig. 4. (A) Correlation between IL-23 gene expression level and sputum 
neutrophil percentage. (B) Sputum IL-23 gene expression according to airway 
inflammatory phenotype. (A) • represent subjects with chronic airway diseases, 
Δ represent healthy controls. (B) Data were displayed as Box and Whiskers 
(Min-Max). Mann-Whitney test was used to compare eosinophilic and neutro-
philic phenotype. Eosinophilic phenotype: sputum eosinophil count ≥ 3%, 
neutrophilic: sputum neutrophil count ≥ 76%. Those who combined both were 
not considered in this analysis. 








































Fig. 5. (A) Correlation between TSLP gene expression level and sputum 
eosinophil count. (B) Correlation between TSLP gene expression level and 
sputum eosinophil percentage. 
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